Trastuzumab Not Yet Recruiting Phase 2 Trials for Cancer, Breast / Her2-Positive Breast Cancer Treatment

IndicationsStatusPurposePhase
Not Yet RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT0336767612 weekS Adjuvant dOcetaxel Plus trastuzumaB in Patients With Small, Node-negative, HER2-positive Breast cancER (SOBER)
NCT03765983GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases
NCT03747120Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab